ProTRAIT

14 August 2018

In the Netherlands, the Ministry of Health has licensed four centers to treat a total of 2200 patients per year with proton therapy. As this is technology new to our country, these licenses oblige the centers to pool all treatment related data into a nation-wide registry. This allows the evaluation of the technology’s efficacy, complications and cost-effectiveness. The ProTRAIT project takes care of the ICT-infrastructure of this registry.

The centers participating in ProTRAIT are:
- UMCG, department of Radiation Oncology (GPTC)
- Maastro Clinic (ZonPTC)
- NKI, AVL department of Radiation Oncology (APTC)
- Leiden UMC, department of Radiation Oncology (HollandPTC)
- Erasmus MC, department of Radiation Oncology (HollandPTC)
- VUmc, department of Radiation Oncology (APTC)
- AMC, department of Radiation Oncology (APTC)

ProTRAIT develops the registry and its ICT-infrastructure for the evaluation of the added value of proton therapy. The registry furthermore ensures that the NTCP-models used for patient selection are continually evaluated and updated, optimizing the application of proton therapy (Rapid Learning Health Care System).

The project’s four main goals are:

A tumor-specific registration programs for all cancer indications that will be treated with proton therapy in the Netherlands;
An automated ICT-infrastructure that allows nation-wide model-based validation by linking prospective data repositories (PROMs, complications, local control, survival, etc.) with DICOM-RT data from those centers involved in proton therapy.
An ICT-infrastructure for conducting phase I, II and II clinical trials.
An ICT-infrastructure for the quality assurance (QUART) of these clinical trials, including Randomized Controlled Trials (RCTs).